Suzanne Brissette
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Suzanne Brissette has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Didier Jutras-Aswad
Université de Montréal
4 shared publications - Gabriel Bastien
Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, 2900 boul. Edouard-Montpetit, Montréal, Québec H3T 1J4, Canada; Research Centre, Centre Hospitalier de l'Université de Montréal (CRCHUM), 900 Saint-Denis Street, Montréal, Québec H2X 0A9, Canada
3 shared publications - Bernard Le Foll
University of Toronto
2 shared publications - Christina McAnulty
Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, 2900 boul. Edouard-Montpetit, Montréal, Québec H3T 1J4, Canada; Research Centre, Centre Hospitalier de l'Université de Montréal (CRCHUM), 900 Saint-Denis Street, Montréal, Québec H2X 0A9, Canada
2 shared publications - Laurent Elkrief
Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada; Research Centre, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada
2 shared publications Louis-Christophe Juteau
2 shared publications
Latest Publications
- 5 April 2024
- Published by Taylor & Francis in Journal of Dual Diagnosis
- Vol. 20 (3) , 189-200
Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial
To evaluate the impact of depressive symptom severity on opioid use and treatment retention in individuals with prescription-type opioid use disorder (POUD). We analyzed data from a multi-centric, pragmatic, open-label, randomized controlled trial comparing buprenorphine/naloxone to methadone models of care in 272 individuals with POUD. Opioid use was self-reported every two weeks for 24 weeks using the Timeline Followback. Depressive symptom severity was self-reported with the Beck Depression Inventory at baseline, week 12 and week 24. Baseline depressive symptom severity was not associated with opioid use nor treatment retention. At week 12, moderate depressive symptoms were associated with greater opioid use while mild to severe depressive symptoms were associated with lowered treatment retention. At week 24, moderate depressive symptoms were associated with greater opioid use. Ongoing depressive symptoms lead to poorer outcomes in POUD. Clinicians are encouraged to use integrative approaches to optimize treatment outcomes. This study was registered in ClinicalTrials.gov (NCT03033732) on January 27th, 2017, prior to participants enrollment.
- 5 April 2024
- Published by Taylor & Francis in Journal of Dual Diagnosis
- Vol. 20 (3) , 189-200
Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial
To evaluate the impact of depressive symptom severity on opioid use and treatment retention in individuals with prescription-type opioid use disorder (POUD). We analyzed data from a multi-centric, pragmatic, open-label, randomized controlled trial comparing buprenorphine/naloxone to methadone models of care in 272 individuals with POUD. Opioid use was self-reported every two weeks for 24 weeks using the Timeline Followback. Depressive symptom severity was self-reported with the Beck Depression Inventory at baseline, week 12 and week 24. Baseline depressive symptom severity was not associated with opioid use nor treatment retention. At week 12, moderate depressive symptoms were associated with greater opioid use while mild to severe depressive symptoms were associated with lowered treatment retention. At week 24, moderate depressive symptoms were associated with greater opioid use. Ongoing depressive symptoms lead to poorer outcomes in POUD. Clinicians are encouraged to use integrative approaches to optimize treatment outcomes. This study was registered in ClinicalTrials.gov (NCT03033732) on January 27th, 2017, prior to participants enrollment.
- Open Access
- 30 March 2023
- Published by Elsevier in Journal of Substance Use and Addiction Treatment
- Vol. 149, 209031
Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study
- 30 March 2023
- Published by Elsevier in Journal of Substance Use and Addiction Treatment
- Vol. 149, 209031
Open AccessDifferential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study
- Open Access
- 31 March 2022
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 216, 173376
Cannabidiol effects on cognition in individuals with cocaine use disorder: Exploratory results from a randomized controlled trial
- 31 March 2022
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 216, 173376
Open AccessCannabidiol effects on cognition in individuals with cocaine use disorder: Exploratory results from a randomized controlled trial
- Open Access
- 1 September 2021
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 226, 108857
Preferences for research design and treatment of comorbid depression among patients with an opioid use disorder: A cross-sectional discrete choice experiment
- 1 September 2021
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 226, 108857
Open AccessPreferences for research design and treatment of comorbid depression among patients with an opioid use disorder: A cross-sectional discrete choice experiment
- 6 February 2020
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 14 (6) , 480-488
Physician Communication in Injectable Opioid Agonist Treatment: Collecting Patient Ratings With the Communication Assessment Tool
Objective: Patient ratings of physician communication in the setting of daily injectable opioid agonist treatment are reported. Associations between communication items and demographic, health, drug use, and treatment characteristics are explored. Methods: Participants (n = 121) were patients receiving treatment for opioid use disorder with hydromorphone (an opioid analgesic) or diacetylmorphine (medical grade heroin). Ratings of physician communication were collected using the 14-item Communication Assessment Tool. Items were dichotomized and associations were explored using univariate and multivariable logistic regression models for each of the 14 items. Results: Ratings of physician communication were lower than reported in other populations. In nearly all of the 14 multivariable models, participants with more physical health problems and with lower scores for treatment drug liking had lower odds of rating physician communication as excellent. Conclusions: In physician interactions with patients with opioid use disorder, there is a critical need to address comorbid physical health problems and account for patient medication preferences. Practice Implications: Findings reinforce the role physicians can play in communicating with patients about their comorbid conditions and about medication preferences. In the patient-physician interaction efforts to meet patients’ evolving treatment needs and preferences can be made by offering patients access to all available evidence-based treatments.
- 6 February 2020
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 14 (6) , 480-488
Physician Communication in Injectable Opioid Agonist Treatment: Collecting Patient Ratings With the Communication Assessment Tool
Objective: Patient ratings of physician communication in the setting of daily injectable opioid agonist treatment are reported. Associations between communication items and demographic, health, drug use, and treatment characteristics are explored. Methods: Participants (n = 121) were patients receiving treatment for opioid use disorder with hydromorphone (an opioid analgesic) or diacetylmorphine (medical grade heroin). Ratings of physician communication were collected using the 14-item Communication Assessment Tool. Items were dichotomized and associations were explored using univariate and multivariable logistic regression models for each of the 14 items. Results: Ratings of physician communication were lower than reported in other populations. In nearly all of the 14 multivariable models, participants with more physical health problems and with lower scores for treatment drug liking had lower odds of rating physician communication as excellent. Conclusions: In physician interactions with patients with opioid use disorder, there is a critical need to address comorbid physical health problems and account for patient medication preferences. Practice Implications: Findings reinforce the role physicians can play in communicating with patients about their comorbid conditions and about medication preferences. In the patient-physician interaction efforts to meet patients’ evolving treatment needs and preferences can be made by offering patients access to all available evidence-based treatments.